Bunkerhill Health has secured $55 million in total funding after closing a Series B led by Khosla Ventures. The startup aims to embed agentic AI deeper into hospital workflows by providing a platform for health systems to create custom clinical AI agents that not only document but also triage, prioritize, and route patients.
- Carebricks platform allows hospitals to build and deploy their own AI agents
- Over 20 AI agents live at University of Texas Medical Branch handling patient triage and routing
- Funding round led by Khosla Ventures brings total investment to $55 million
What happened
Bunkerhill Health announced the completion of a Series B funding round led by Khosla Ventures, raising a total of $55 million to further develop its Carebricks platform. Unlike typical AI healthcare tools that serve as passive assistants, this platform enables health systems to create customizable AI agents that actively manage clinical workflows. These agents can analyze unstructured patient data, prioritize urgent cases, and route patients to appropriate care teams.
This approach has been piloted at the University of Texas Medical Branch, where more than 20 AI agents are currently operational. The agents are designed to support different medical specialties, including a coronary calcium agent with an FDA-cleared algorithm that alerted clinicians to a patient’s imminent heart attack risk, subsequently facilitating life-saving surgery. Other agents have targeted bottlenecks in nephrology and lung care by reducing wait times and expediting urgent case processing.
Why it matters
The shift from AI systems that primarily document clinical encounters to ones that take autonomous action marks a significant evolution in healthcare AI. Bunkerhill’s platform champions this ‘agentic AI’ model, aligning with broader enterprise trends that favor platforms allowing organizations to deploy fleets of AI agents rather than relying on fragmented point solutions. This shift aims to convert clinical protocols and insights into actionable workflows, addressing chronic staffing shortages and inefficiencies in hospitals.
However, the adoption of autonomous clinical AI agents introduces new challenges related to regulatory compliance, liability, and oversight. Only some of Bunkerhill’s algorithms have FDA clearance, and responsibility for clinical decisions made or influenced by AI agents remains a critical question. Independent evaluation of clinical outcomes and broader peer-reviewed validation will be essential to ensuring safe and effective scaling across healthcare systems.
What to watch next
As Bunkerhill Health advances its platform expansion, the healthcare and investor communities will be closely monitoring how broadly health systems adopt agentic AI. The real test lies in whether these agents can consistently improve clinical outcomes without introducing unintended risks, while managing the complexities of liability and regulatory oversight. Demonstrated success beyond single-institution pilots will be vital for building trust and encouraging widespread deployment.